JO3489B1 - مركبات تراي أزولوبيريميدين واستخداماتها - Google Patents

مركبات تراي أزولوبيريميدين واستخداماتها

Info

Publication number
JO3489B1
JO3489B1 JOP/2015/0331A JOP20150331A JO3489B1 JO 3489 B1 JO3489 B1 JO 3489B1 JO P20150331 A JOP20150331 A JO P20150331A JO 3489 B1 JO3489 B1 JO 3489B1
Authority
JO
Jordan
Prior art keywords
triazolopyrimidines
shireen
image002
appdata
prc2
Prior art date
Application number
JOP/2015/0331A
Other languages
English (en)
Inventor
Sendzik Martin
Mi Yuan
Huang Ying
Justin Gu Xiang-Ju
Man Chan Ho
Yu Zhengtian
Yue Ji (Jeff) Zhang
Zhao Kehao
Sun Yongfeng
Zhang Hailong
Li Ling
Zhang Man
Zhang Qiong
Qi Wei
Wang Long
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Application granted granted Critical
Publication of JO3489B1 publication Critical patent/JO3489B1/ar

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/541—Non-condensed thiazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

يتعلق الاختراع الحالي بتوفير مركب من الصيغة (I)، أو ملح مقبول صيدلانيا منه، والذي اتضح أنه مفيد في علاج مرض أو اضطراب ناتج عن PRC2: حيث R1، وR2، وR3، وR4، وR5، وn هي كما هي محددة هن <img src="file:///C:/Users/shireen.s/AppData/Local/Temp/msohtmlclip1/01/clip_image002.gif" />
JOP/2015/0331A 2014-12-23 2015-12-22 مركبات تراي أزولوبيريميدين واستخداماتها JO3489B1 (ar)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN2014094644 2014-12-23
CN2015095320 2015-11-23

Publications (1)

Publication Number Publication Date
JO3489B1 true JO3489B1 (ar) 2020-07-05

Family

ID=55071101

Family Applications (1)

Application Number Title Priority Date Filing Date
JOP/2015/0331A JO3489B1 (ar) 2014-12-23 2015-12-22 مركبات تراي أزولوبيريميدين واستخداماتها

Country Status (40)

Country Link
US (5) US10220036B2 (ar)
EP (1) EP3237418B1 (ar)
JP (1) JP6736559B2 (ar)
KR (1) KR102534028B1 (ar)
CN (1) CN107108637B (ar)
AU (1) AU2015370524B2 (ar)
BR (1) BR112017010354B8 (ar)
CA (1) CA2969090C (ar)
CL (1) CL2017001572A1 (ar)
CO (1) CO2017005992A2 (ar)
CR (1) CR20170285A (ar)
CY (1) CY1121901T1 (ar)
DK (1) DK3237418T3 (ar)
DO (1) DOP2017000149A (ar)
EA (1) EA032416B1 (ar)
EC (1) ECSP17047153A (ar)
ES (1) ES2722048T3 (ar)
GT (1) GT201700146A (ar)
HR (1) HRP20190805T1 (ar)
HU (1) HUE043060T2 (ar)
IL (1) IL252135B (ar)
JO (1) JO3489B1 (ar)
LT (1) LT3237418T (ar)
ME (1) ME03385B (ar)
MX (1) MX375970B (ar)
MY (1) MY186837A (ar)
NZ (1) NZ731664A (ar)
PE (1) PE20171307A1 (ar)
PH (1) PH12017501016B1 (ar)
PL (1) PL3237418T3 (ar)
PT (1) PT3237418T (ar)
RS (1) RS58679B1 (ar)
SG (1) SG11201703880VA (ar)
SI (1) SI3237418T1 (ar)
SV (1) SV2017005472A (ar)
TN (1) TN2017000204A1 (ar)
TW (1) TWI694076B (ar)
UA (1) UA120945C2 (ar)
UY (1) UY36462A (ar)
WO (1) WO2016103155A1 (ar)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10220036B2 (en) * 2014-12-23 2019-03-05 Novartis Ag Triazolopyrimidine compounds and uses thereof
EP3464643A4 (en) * 2016-06-01 2020-04-01 Epizyme Inc USE OF EZH2 INHIBITORS FOR THE TREATMENT OF CANCER
CA3027246A1 (en) * 2016-06-20 2017-12-28 Novartis Ag Crystalline forms of triazolopyrimidine compound
JP2019524872A (ja) * 2016-06-20 2019-09-05 ノバルティス アーゲー 癌の治療に有用なイミダゾピリミジン化合物
JP2019522049A (ja) * 2016-06-20 2019-08-08 ノバルティス アーゲー トリアゾロピリジン化合物及びその使用
WO2018013597A1 (en) 2016-07-12 2018-01-18 Revolution Medicines, Inc. 2,5-disubstituted 3-methyl pyrazines and 2,5,6-trisubstituted 3-methyl pyrazines as allosteric shp2 inhibitors
CN106831601A (zh) * 2017-01-13 2017-06-13 河北博伦特药业有限公司 一种2‑氨基甲基嘧啶盐酸盐及其衍生物的合成方法
BR112019014527A2 (pt) 2017-01-23 2020-02-27 Revolution Medicines, Inc. Compostos de piridina como inibidores de shp2 alostéricos
AR110740A1 (es) 2017-01-23 2019-05-02 Revolution Medicines Inc Compuestos bicíclicos como inhibidores alostéricos de shp2
WO2018170290A1 (en) * 2017-03-15 2018-09-20 Fulcrum Therapeutics, Inc. Compositions and methods for increasing fmr1 expression
US10266542B2 (en) 2017-03-15 2019-04-23 Mirati Therapeutics, Inc. EZH2 inhibitors
CN109963854B (zh) * 2017-03-16 2022-04-12 江苏恒瑞医药股份有限公司 杂芳基并[4,3-c]嘧啶-5-胺类衍生物、其制备方法及其在医药上的应用
AU2018275123A1 (en) 2017-06-02 2020-01-30 Epizyme, Inc. Use of EZH2 inhibitors for treating cancer
WO2019062435A1 (zh) * 2017-09-28 2019-04-04 中国科学院上海药物研究所 三氮唑并嘧啶、三氮唑并吡啶化合物及其组合物用于治疗prc2介导的疾病
CN109575013A (zh) * 2017-09-28 2019-04-05 中国科学院上海药物研究所 三氮唑并嘧啶、三氮唑并吡啶化合物及其组合物用于治疗prc2介导的疾病
CN111212834B (zh) 2017-10-12 2024-01-19 锐新医药公司 作为变构shp2抑制剂的吡啶、吡嗪和三嗪化合物
CN109867645B (zh) * 2017-12-05 2021-09-14 中国医学科学院药物研究所 一种2,2-二氟-2,3-二氢取代苯并呋喃类化合物的合成方法
BR112020009757A2 (pt) * 2017-12-15 2020-11-03 Revolution Medicines, Inc. compostos policíclicos como inibidores alostéricos de shp2
CN109942556A (zh) * 2017-12-21 2019-06-28 上海青煜医药科技有限公司 嘧啶酮化合物及其应用
CN111630042A (zh) * 2018-01-23 2020-09-04 巴斯夫欧洲公司 吡啶衍生物的卤化
PT3746446T (pt) * 2018-01-31 2022-07-18 Mirati Therapeutics Inc Inibidores de prc2
CN110156787B (zh) * 2018-02-13 2021-11-02 中国科学院上海药物研究所 一种三氮唑并嘧啶衍生化合物、包含其的药物组合物及其用途
CN110563722A (zh) * 2018-06-06 2019-12-13 上海青煜医药科技有限公司 吡啶或哒嗪并环化合物及其应用
CN110734436A (zh) * 2018-07-19 2020-01-31 上海青煜医药科技有限公司 嘧啶或吡嗪并环化合物及其应用
CA3120791A1 (en) * 2018-11-30 2020-06-04 Tuojie Biotech (Shanghai) Co., Ltd. Pyrimidine and five-membered nitrogen heterocycle derivative, preparation method therefor, and medical uses thereof
CN111518100A (zh) * 2019-02-02 2020-08-11 上海青煜医药科技有限公司 环丙烯并苯并呋喃取代的氮杂芳基化合物及其应用
KR20210151833A (ko) * 2019-03-15 2021-12-14 풀크럼 쎄러퓨틱스, 인코포레이티드 Eed 및 prc2 조절제로서 마크로사이클릭 아졸로피리딘 유도체
KR102875195B1 (ko) * 2019-04-03 2025-10-22 케미테라스, 인크. 티민 핵산 염기를 베이스로 하는 트리아졸로피리미딘류 및 그 제조 방법
EP3959214A1 (en) * 2019-04-22 2022-03-02 Mirati Therapeutics, Inc. Naphthyridine derivatives as prc2 inhibitors
US11814734B2 (en) 2019-05-13 2023-11-14 Ecolab Usa Inc. 1,2,4-triazolo[1,5-a] pyrimidine derivative as copper corrosion inhibitor
WO2020247706A1 (en) * 2019-06-05 2020-12-10 Athenex, Inc. Methods of treating and/or preventing psoriasis
EP3980422A1 (en) 2019-06-05 2022-04-13 Mirati Therapeutics, Inc. Imidazo[1,2-c]pyrimidine derivatives as prc2 inhibitors for treating cancer
JP7738909B2 (ja) 2019-07-16 2025-09-16 ザ・リージェンツ・オブ・ザ・ユニバーシティ・オブ・ミシガン Ｅｅｄ阻害剤としてのイミダゾピリミジンおよびその使用
PH12022550441A1 (en) 2019-08-22 2022-12-19 Blueray Therapeutics Shanghai Co Ltd Azaheteroaryl compound and application thereof
CN114746414B (zh) * 2019-09-26 2024-10-18 诺华公司 氮杂-喹啉化合物及其用途
CA3156546A1 (en) * 2019-11-01 2021-05-06 Wei Qi Substituted [1,2,4]triazolo-[4,3-c]pyrimidine compounds and use thereof as eed inhibitors
CN113004233B (zh) * 2019-12-18 2022-12-20 南京优氟医药科技有限公司 一种用于制备prc2抑制剂的化合物、其制备方法和用途
CN111333655B (zh) * 2020-04-13 2021-07-13 武汉工程大学 一种三唑并嘧啶类化合物及其制备方法和应用
US12221427B2 (en) 2020-05-11 2025-02-11 Ascentage Pharma (Suzhou) Co., Ltd. Preparation method of (5-fluoro-2,3-dihydrobenzofuran-4-yl)methanamine or its salt, and intermediates thereof
CA3185154A1 (en) * 2020-05-28 2021-12-02 Novartis Ag Dosing regimens for n-((5-fluoro-2,3-dihydrobenzofuran-4-yl)methyl)-8-(2-methylpyridin-3-yl)-[1,2,4]triazolo[4,3-c]pyrimidin-5-amine, or a pharmaceutically acceptable salt thereof, for use in treating prc2-mediated diseases or disorders
CN114907385A (zh) 2021-02-10 2022-08-16 上海青煜医药科技有限公司 氮杂芳基化合物、其制备方法及应用
CN115703799B (zh) * 2021-08-11 2024-11-08 上海青煜医药科技有限公司 氮杂芳基化合物、其制备方法及应用
CN117384153A (zh) * 2022-07-12 2024-01-12 上海赛岚生物科技有限公司 一类甲基转移酶抑制剂及其用途
WO2024215699A1 (en) * 2023-04-11 2024-10-17 Oric Pharmaceuticals, Inc. Treatment of t-cell lymphoma

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2779780A (en) 1955-03-01 1957-01-29 Du Pont 1, 4-diamino-2, 3-dicyano-1, 4-bis (substituted mercapto) butadienes and their preparation
EP0647450A1 (en) 1993-09-09 1995-04-12 BEHRINGWERKE Aktiengesellschaft Improved prodrugs for enzyme mediated activation
IL143236A0 (en) 1998-12-16 2002-04-21 Warner Lambert Co Treatment of arthritis with mek inhibitors
NL1014106C2 (nl) 2000-01-18 2001-07-20 Univ Amsterdam Werkwijze voor het detecteren van een pathologische afwijking bij een cel, een antistof en een assay kit.
DZ3401A1 (fr) 2000-07-19 2002-01-24 Warner Lambert Co Esters oxygenes d'acides 4-iodophenylamino benzhydroxamiques
SE519662C2 (sv) 2001-07-04 2003-03-25 Asept Int Ab Ventilanordning vid utportioneringsanordningar
AU2002357667A1 (en) * 2001-10-24 2003-05-06 Iconix Pharmaceuticals, Inc. Modulators of phosphoinositide 3-kinase
US6921762B2 (en) * 2001-11-16 2005-07-26 Amgen Inc. Substituted indolizine-like compounds and methods of use
CN104876904A (zh) 2002-03-08 2015-09-02 卫材R&D管理株式会社 用作医药品的大环化合物
TWI338685B (en) 2002-03-13 2011-03-11 Array Biopharma Inc N3 alkylated benzimid azole derivatives as mek inhibitors
GB0228900D0 (en) 2002-12-11 2003-01-15 Ml Lab Plc Cancer Immunotherapy
JP2004238296A (ja) 2003-02-04 2004-08-26 Kissei Pharmaceut Co Ltd 新規なトリアゾロピリミジン誘導体、それを含有する医薬組成物およびそれらの用途
JP2007524596A (ja) 2003-02-28 2007-08-30 トランスフォーム・ファーマシューティカルズ・インコーポレイテッド 共結晶医薬組成物
AU2004256425A1 (en) 2003-06-09 2005-01-20 The Regents Of The University Of Michigan Compositions and methods for treating and diagnosing cancer
US20060246505A1 (en) 2003-09-02 2006-11-02 Reinhard Walther Modulation of the synthesis of insulin
EP1765994B1 (en) 2004-06-01 2009-11-18 The University of North Carolina at Chapel Hill Reconstituted histone methyltransferase complex and methods of identifying modulators thereof
GB0510390D0 (en) 2005-05-20 2005-06-29 Novartis Ag Organic compounds
US7452892B2 (en) 2005-06-17 2008-11-18 Bristol-Myers Squibb Company Triazolopyrimidine cannabinoid receptor 1 antagonists
CA2618218C (en) 2005-07-21 2015-06-30 Ardea Biosciences, Inc. N-(arylamino)-sulfonamide inhibitors of mek
JO2660B1 (ar) 2006-01-20 2012-06-17 نوفارتيس ايه جي مثبطات الكاينيز Pi-3 وطرق استخدامها
EP2041575A2 (en) 2006-03-31 2009-04-01 Ordway Research Institute Prognostic and diagnostic method for cancer therapy
CA2673784A1 (en) 2006-12-27 2008-07-10 Usc Stevens-University Of Southern California Dna methylation markers based on epigenetic stem cell signatures in cancer
WO2009017670A2 (en) 2007-07-26 2009-02-05 University Of Massachusetts Ras-mediated epigenetic silencing effectors and uses thereof
WO2009026720A1 (en) 2007-08-29 2009-03-05 Methylgene Inc. Processes and intermediates for preparing fused heterocyclic kinase inhibitors
CA2699202C (en) 2007-09-12 2016-09-27 F. Hoffmann-La Roche Ag Combinations of phosphoinositide 3-kinase inhibitor compounds and chemotherapeutic agents, and methods of use
US8354528B2 (en) 2007-10-25 2013-01-15 Genentech, Inc. Process for making thienopyrimidine compounds
US8168784B2 (en) 2008-06-20 2012-05-01 Abbott Laboratories Processes to make apoptosis promoters
GB0822248D0 (en) 2008-12-05 2009-01-14 Medical Res Council Crystal meths
WO2010111712A2 (en) 2009-03-27 2010-09-30 Cold Spring Harbor Laboratory Identification of rnai targets and use of rnai for rational therapy of chemotherapy-resistant leukemia and other cancers
CN102020643A (zh) 2009-09-22 2011-04-20 上海恒瑞医药有限公司 二氢喋啶酮类衍生物、其制备方法及其在医药上的应用
TW201200518A (en) 2010-03-10 2012-01-01 Kalypsys Inc Heterocyclic inhibitors of histamine receptors for the treatment of disease
PT2566327T (pt) * 2010-05-07 2017-05-26 Glaxosmithkline Llc Indoles
RU2765155C2 (ru) 2010-09-10 2022-01-26 Эпизайм, Инк. Ингибиторы ezh2 человека и способы их применения
WO2012151277A1 (en) 2011-05-02 2012-11-08 Applied Informatic Solutions, Inc. Kits and methods for selecting a treatment for ovarian cancer
US20140213475A1 (en) 2011-07-14 2014-07-31 University Of Massachusetts Methods of diagnosing cancer using epigenetic biomarkers
EP2760452A4 (en) 2011-09-30 2015-04-01 Glaxosmithkline Llc METHODS OF TREATING CANCER
EP3536314A1 (en) 2012-03-12 2019-09-11 Epizyme, Inc. Inhibitors of human ezh2, and methods of use thereof
US20150291598A1 (en) 2012-11-19 2015-10-15 Novartis Ag Compounds and compositions for the treatment of parasitic diseases
EP2934531A4 (en) 2012-12-19 2016-06-15 Glaxosmithkline Llc COMBINATION
WO2014124326A1 (en) 2013-02-08 2014-08-14 Stem Centrx, Inc. Novel multispecific constructs
PE20160044A1 (es) 2013-02-11 2016-02-11 Constellation Pharmaceuticals Inc Moduladores de las enzimas modificadoras de los metilos, composiciones que los comprenden y sus usos
RU2015139054A (ru) 2013-03-14 2017-04-19 Дженентек, Инк. Способы лечения рака и профилактики лекарственной резистентности рака
EP2970306A4 (en) 2013-03-15 2016-08-03 Epizyme Inc SUBSTITUTED 6.5-CONDENSED BICYCLIC HETEROARYL COMPOUNDS
WO2014151142A1 (en) 2013-03-15 2014-09-25 Constellation Pharmaceuticals, Inc. Modulators of methyl modifying enzymes, compositions and uses thereof
AU2015217152A1 (en) 2014-02-11 2016-08-11 Mitokinin, Inc. Compositions and methods using the same for treatment of neurodegenerative and mitochondrial disease
KR102486616B1 (ko) 2014-11-14 2023-01-09 바스프 에스이 질화작용 억제제로서의 벤질프로파르길에테르
SI3033944T1 (en) 2014-12-16 2018-06-29 Omya International Ag Calcium carbonate for plant protection
US10220036B2 (en) * 2014-12-23 2019-03-05 Novartis Ag Triazolopyrimidine compounds and uses thereof
MA41272A (fr) 2014-12-23 2017-10-31 Adama Makhteshim Ltd 5-fluoro-4-imino-3-(alkyle/alkyle substitué)-1-(arylsulfonyl)-3,4-dihydropyrimidin-2(1h)-one en tant que traitement des semences
GB201501017D0 (en) 2014-12-23 2015-03-04 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against hepatocellular carcinoma (HCC) and other cancers

Also Published As

Publication number Publication date
AU2015370524B2 (en) 2018-11-01
HRP20190805T1 (hr) 2019-06-28
DK3237418T3 (da) 2019-05-13
JP6736559B2 (ja) 2020-08-05
ES2722048T3 (es) 2019-08-07
IL252135B (en) 2020-06-30
ME03385B (me) 2020-01-20
US11931363B2 (en) 2024-03-19
IL252135A0 (en) 2017-07-31
SI3237418T1 (sl) 2019-06-28
UY36462A (es) 2016-07-29
CN107108637B (zh) 2019-10-29
TWI694076B (zh) 2020-05-21
US20190142837A1 (en) 2019-05-16
EP3237418B1 (en) 2019-01-30
MY186837A (en) 2021-08-25
EA201791420A1 (ru) 2017-10-31
CL2017001572A1 (es) 2018-01-12
PE20171307A1 (es) 2017-09-05
US10220036B2 (en) 2019-03-05
SG11201703880VA (en) 2017-07-28
US11207325B2 (en) 2021-12-28
CA2969090A1 (en) 2016-06-30
US9580437B2 (en) 2017-02-28
US20200323859A1 (en) 2020-10-15
EP3237418A1 (en) 2017-11-01
NZ731664A (en) 2024-02-23
US20160176882A1 (en) 2016-06-23
LT3237418T (lt) 2019-05-10
AU2015370524A1 (en) 2017-06-01
HUE043060T2 (hu) 2019-07-29
US20170348312A1 (en) 2017-12-07
MX2017008529A (es) 2017-10-25
PT3237418T (pt) 2019-05-23
CN107108637A (zh) 2017-08-29
MX375970B (es) 2025-03-06
WO2016103155A1 (en) 2016-06-30
PH12017501016A1 (en) 2017-12-11
KR20170095882A (ko) 2017-08-23
TW201629065A (zh) 2016-08-16
TN2017000204A1 (en) 2018-10-19
PL3237418T3 (pl) 2019-07-31
GT201700146A (es) 2019-06-12
BR112017010354B1 (pt) 2022-09-20
CR20170285A (es) 2017-08-21
US20230033320A1 (en) 2023-02-02
CO2017005992A2 (es) 2017-10-20
UA120945C2 (uk) 2020-03-10
BR112017010354A2 (pt) 2017-12-26
RS58679B1 (sr) 2019-06-28
PH12017501016B1 (en) 2017-12-11
EA032416B1 (ru) 2019-05-31
BR112017010354B8 (pt) 2022-10-18
CY1121901T1 (el) 2020-10-14
SV2017005472A (es) 2018-06-12
CA2969090C (en) 2023-05-02
JP2018500342A (ja) 2018-01-11
DOP2017000149A (es) 2017-07-15
ECSP17047153A (es) 2019-02-28
KR102534028B1 (ko) 2023-05-19

Similar Documents

Publication Publication Date Title
JO3489B1 (ar) مركبات تراي أزولوبيريميدين واستخداماتها
EA201501142A1 (ru) Гетероциклические соединения в качестве средств для борьбы с вредителями
JOP20190194A1 (ar) مركبات نيوكليوتيدات ثنائية حلقية لعلاج السرطان
EA201692219A1 (ru) Способы получения противовирусных соединений
MX391812B (es) Agonista fxr derivado de esteroides.
UA118259C2 (uk) Гетероциклічні аміди як інгібітори кінази
MX389684B (es) Anticuerpos anti tigit.
EA201890058A1 (ru) Производное глюкагона и композиция, содержащая длительно действующий конъюгат этого производного
EA201692301A1 (ru) Производные бороновой кислоты и их терапевтическое применение
EA201591004A1 (ru) Производные бороновой кислоты и их терапевтическое применение
EA201692203A1 (ru) Соединения, ингибирующие tank-связывающую киназу
MX392779B (es) Anticuerpos anti-cd27
EA201691216A1 (ru) Композиции линаклотида с замедленным высвобождением
EA201790395A1 (ru) Производные аминотриазина, подходящие для применения в качестве соединений-ингибиторов tank-связывающей киназы
EA201690478A1 (ru) НОВЫЕ ПРОИЗВОДНЫЕ ТРИАЗОЛ[4,5-d]ПИРИМИДИНА
EA201690687A1 (ru) Ингибиторы репликации вируса иммунодефицита
JO3579B1 (ar) مُعدِلات تفاغرية سالبة لمستقبل nr2b من المركب n-ألكيل أريل-5-أوكسي أريل-ثامن هيدرو-خماسي الحلقة [c] بيرول
MA38404A1 (fr) Nouveaux dérivés de pyridine
PH12017500095A1 (en) Imidazopyridazine compounds
MY194307A (en) Pyridone derivative having tetrahydropyranylmethyl group
EA201692550A1 (ru) Соединения, содержащие систему 1,1&#39;,2,5&#39;-тетрагидроспиро[индол-3,2&#39;-пиррол]-2,5&#39;-диона в качестве ингибиторов белок-белкового взаимодействия p53-mdm2
EA201892246A1 (ru) Производные аминотиазола, полученные в качестве противовирусных средств
EA201992832A1 (ru) Подкожное введение adamts13
EA201691983A1 (ru) Пиридин-2-амиды, пригодные в качестве агонистов cb2
EA201890632A1 (ru) Хиральные фосфорамидимидаты и их производные